In EGFR TKI erlotinib-resistant lung cancer cells and colon cancer cells, the induced insulin-like growth factor-I receptor activation is implicated in resistance to erlotinib [12,13]. The gene discussed is EGFR; the disease is malignant colon neoplasm.